Your own T cells are collected, genetically reprogrammed to recognise your cancer, multiplied, and re-infused — a living drug that has driven complete remissions in leukaemias and lymphomas that had run out of options. China approved multiple domestic CAR-T products (the world's second-largest approved arsenal) at prices of roughly a tenth of US list prices, and runs one of the world's largest CAR-T clinical trial portfolios.
What it treats & who qualifies
- Relapsed or refractory B-cell malignancies: diffuse large B-cell lymphoma, follicular lymphoma, ALL.
- Patients whose disease has failed two or more prior lines, or after transplant failure.
- Medically fit for lymphodepletion; organ function and infection screening passed.
- Other cancers through clinical-trial screening — the eligibility review is free and honest.
Why patients travel to China for this
- China has multiple domestically approved CAR-T products (NMPA, 2021 onward) — with domestic pricing at roughly US$45,000–85,000 versus US$370,000–530,000 list prices abroad.
- China runs among the largest CAR-T clinical trial portfolios in the world — including targets beyond CD19 and registries that enrol patients whose commercial options are exhausted.
- Treatment is delivered inside fully credentialed transplant-and-cell-therapy units with 24/7 cytokine-release management.
Treatment options, compared
| Option | Best suited for | What it means in practice |
|---|
| Approved domestic CAR-T products (CD19) | Relapsed/refractory lymphoma and ALL | Roughly a tenth of US list prices; NMPA-approved since 2021. |
|---|
| Clinical-trial CAR-T (next-generation targets) | Cancers without approved products | China runs one of the broadest trial portfolios; screening costs nothing. |
|---|
| Allogeneic ('off-the-shelf') CAR-T trials | Patients ineligible for autologous manufacture | Emerging option, trial-based. |
|---|
The procedure, step by step
- Eligibility review: pathology, prior-therapy records, organ function, disease burden assessment.
- Lymphodepleting chemotherapy prepares the immune niche (hospital admission).
- Your CAR-T product (manufactured earlier from your collected cells, or an approved off-the-shelf-matched product) is infused — over minutes.
- Days 1–14 are monitored in hospital for cytokine release syndrome and neurotoxicity, with tocilizumab and steroids on standby.
- Response assessment at day 28; long-term follow-up tracks persistence and late effects.
Cost, hospital stay & recovery
| Typical China cost (reference only) | US$45,000–85,000 for an approved domestic product (including apheresis, lymphodepletion and admission); clinical-trial enrolment costs differ |
|---|
| Typical in-hospital stay | 2–3 weeks in hospital, plus pre-treatment work-up (2–4 weeks) |
|---|
| Return-to-travel timeline | Fly home after day-28 assessment; quarterly follow-ups can be shared with home haematology |
|---|
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
Recovery, week by week
- Weeks −4 to 0: Leukapheresis and manufacturing (~2 weeks) plus eligibility work-up.
- Day −5 to −1: Lymphodepleting chemotherapy as inpatient preparation.
- Day 0: Infusion over minutes; monitoring begins.
- Days 1–14: Inpatient CRS/neurotoxicity watch; tocilizumab and steroids on standby.
- Day 28: Response assessment (PET or marrow); follow-up plan and home-team handover.
Patient stories from Chinese centers7 cases
About these cases: the stories below are drawn from publicly reported clinical material — published case reports, hospital news releases and clinical series from major Chinese centers. Names and identifying details have been changed or omitted. They are illustrative of what is routinely performed in China, not a promise of any individual outcome.
A 34-year-old man from the United States with refractory DLBCL
A domestic CAR-T quote of USD 400,000 and an insurer that prevaricated. A domestically manufactured CAR-T in China at under a tenth of the price; his PET at month three shows complete metabolic response.
Source: Published Chinese CAR-T lymphoma trials; anonymised.
A 41-year-old woman from the United Kingdom with relapsed lymphoma
Third-line options at home ran out. CAR-T infusion in Shanghai after lymphodepletion; cytokine-release syndrome managed textbook-style, and she returned to London in continuous remission.
Source: Hospital-reported international CAR-T case; anonymised.
A 38-year-old man from Kazakhstan with multiply-relapsed DLBCL
Two transplants behind him and no domestic CAR-T programme. His Almaty board had only read about the therapy; Shanghai provided it, and his follow-up scans are now measured in years of nothing happening.
Source: Public clinical reports; anonymised.
A 29-year-old woman from France with relapsed ALL
A disease that relapses fast in adults. Bridging therapy, then CAR-T in Guangzhou; minimal residual disease undetectable at day 28, and her haematologist in Lyon manages the aftercare from shared records.
Source: Published Chinese CAR-T ALL cohorts; anonymised.
A 45-year-old man from Saudi Arabia with post-transplant lymphoma
A complication of his kidney transplant years earlier. CAR-T in Beijing with careful immunosuppression choreography; the lymphoma melted, the kidney kept working.
Source: Hospital-reported complex CAR-T case; anonymised.
A 31-year-old woman from the United Arab Emirates with refractory lymphoma
Her family coordinated everything from Dubai with the hospital's international office. Apheresis, manufacturing, infusion — all in one admission; she was home for Eid in remission.
Source: Hospital-reported CAR-T case; anonymised.
A 36-year-old man from Egypt with relapsed mantle-cell lymphoma
A subtype where CAR-T data are thinnest and Chinese trial experience among the deepest. Infusion in Shanghai; his first clean PET in four years arrived by WeChat before the plane home.
Source: Public clinical trial reports; anonymised.
Frequently asked questions
What are the risks?
Cytokine release syndrome and neurotoxicity are the signature risks — fever, hypotension, confusion — which is why treatment happens inside experienced transplant units with round-the-clock management. Published Chinese series report safety profiles comparable to international registries.
Do I qualify if my cancer is not a lymphoma or leukaemia?
Approved products today target B-cell malignancies; for other cancers the realistic path is often a clinical trial — and China's CAR-T trial portfolio is among the broadest anywhere. WellVoyage screens your records against open-protocol eligibility.
Medical disclaimer: WellVoyage is a medical-travel coordination service, not a medical provider. This guide is general information, not medical advice; treatment decisions rest with your treating physicians. Patient stories are drawn from publicly reported, anonymised material and do not promise any individual outcome. Cost figures are reference ranges; the binding price is your written quote. Hospitals and doctors named on this site are independent third parties, not our partners. In an emergency, contact your local emergency services immediately.